查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1830309

血漿分餾市場（按產品類型、分餾方法、應用和最終用戶分類）—2025-2032 年全球預測

Plasma Fractionation Market by Product Type, Method of Fractionation, Application, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年血漿分餾市場將成長 782.8 億美元，複合年成長率為 9.90%。

主要市場統計數據
基準年2024年 367.7億美元
預計2025年 402.2億美元
預測年份：2032年 782.8億美元
複合年成長率（%） 9.90%

血漿分餾領域處於先進生物製程與龐大臨床需求的交匯點，推動著針對免疫力缺乏、凝血功能障礙和其他危及生命的疾病的關鍵治療方法的發展。分離技術、分析平台和監管協調的最新進展，正在提高製造商和服務供應商的技術期望。同時，對以患者為中心的護理模式和罕見疾病治療的日益關注，正在將商業性重點從商品化供應轉向差異化給藥方式，例如皮下免疫球蛋白治療和綜合患者支持計劃。

在這種動態下，相關人員必須協調日益成長的臨床複雜性與採購高品質血漿、保持批次間一致性以及確保穩健的低溫運輸物流的營運現實。策略相關人員正在優先投資自動化、一次性系統和流程分析技術，以減少差異性並加快放行時間。此外，從血液採集網路到合約分離器，整個價值鏈上的協作正成為一種競爭的必要條件，從而促進融合專業監管和技術專長與能力的夥伴關係關係。

隨著產業的成熟，人們越來越重視可重複的品質和彈性的供應鏈，同時也更加重視服務成本和病患可及性。因此，企業策略也日益多元化，整合卓越的製造能力、專業的產品系列和地理覆蓋，以在維持利潤率完整性的同時獲取臨床價值。

技術突破、監管融合和治療模式轉變如何重塑準備行動和策略重點

過去幾年，技術創新、監管環境的演變以及治療需求的轉變顯著改變了血漿分餾的模式。在上游工程，強化的捐血者篩檢通訊協定和改進的血漿採集基礎設施提高了原料的品質；而在下游，離子交換層析法和超過濾等現代分離方法則提高了關鍵生技藥品的純度和產量。這些製程改進不僅提高了產品的一致性，還使製劑的穩定性和給藥方案得到改善，從而擴大了可治療的適應症範圍。

同時，監管機構對病毒安全性、製程驗證和可比性測試的要求也日益明確，促使企業更新驗證策略並投資於高階分析技術。這種監管明確性降低了新參與企業的技術門檻，但也提高了展示強大生產控制的門檻。在商業性方面，皮下免疫球蛋白和患者自主給藥模式的興起正在再形成分銷和依從性考量，迫使製造商重新思考包裝、劑量靈活性和患者教育計劃。

最後，競爭動態正受到戰略夥伴關係關係、契約製造擴張以及旨在緩解血漿供應區域不平衡的跨境產能投資浪潮的影響。這些變化正在加速從傳統的以批量為中心的營運模式轉向敏捷、以品質主導的平台轉變，這些平台支持差異化療法和更具彈性的供應。

2025 年美國關稅對供應鏈彈性、籌資策略、合約架構和區域製造業的影響

2025年美國加徵關稅為全球血漿分餾供應鏈帶來了重大變數，影響了採購選擇、商業合約和跨國生產策略。關稅相關的成本壓力促使企業重新評估依賴進口的生產模式，並加速關鍵原料、專用試劑和成品藥的本地化進程。為此，企業紛紛尋求多元化的供應商網路，並將製造和填充能力遷移或擴展到更靠近需求中心的地方，以減少貿易摩擦和物流延誤帶來的風險。

此後不久，契約製造製造商和服務提供者開始調整長期協議，因為客戶要求協議中包含應對關稅波動和額外成本轉嫁可能性的條款。這些合約變更強調靈活性、更短的前置作業時間和應急計劃，而採購團隊則優先考慮多源採購和地理冗餘。對於低溫運輸要求複雜或需要即時物流的產品，關稅壓力加劇了對前置作業時間波動和庫存過時的擔憂，凸顯了改善需求預測和緩衝策略的必要性。

貿易政策的轉變引發了策略轉變，而非一次性的成本調整。投資於本地製造能力、透明的成本結構和穩健的供應商關係的公司發現自己更有能力維持業務並保障患者獲得藥品。相較之下，仍嚴重依賴單一國家供應鏈的公司面臨更高的營運風險，必須加快緩解措施以保持供應的連續性。

細分主導的綜合洞察，將產品差異化、分餾技術、臨床應用和最終用戶需求與策略要務聯繫起來

細分分析揭示了產品類型、分餾方法、應用和最終用戶之間的差異化動態，從而塑造了產業參與者的策略重點領域。在產品類型中，白蛋白、凝血因子濃縮物、免疫球蛋白和蛋白酶抑制劑各自展現出獨特的發展路徑。尤其是免疫球蛋白，進一步細分為靜脈注射和皮下注射，給藥途徑的創新影響製劑配方和病患支持需求。這些產品特有的細微差別驅動著不同的研發重點、法規要求和商業化方法。

就製造技術而言，離心、冷沉澱、乙醇沉澱、離子交換層析法和超過濾等技術在資本強度、監管審查和規模經濟方面各有不同。採用層析法和膜技術的公司優先考慮製程強化和分析控制，而依賴沉澱方法的企業則在探索混合製程架構，以提高產量和安全性。血液學、神經病學、腫瘤學和風濕病學等臨床應用領域具有顯著不同的治療價值提案和報銷動態，這些因素為打入市場策略和證據生成計劃提供了資訊。

最後，涵蓋學術機構、臨床研究組織以及醫院和診所的最終使用者環境決定了服務水準期望、法律規範和採購行為。同時，醫院和診所優先考慮可靠的供應、便捷的給藥方式以及能夠確保依從性和安全給藥的支援服務。透過整合這些細分視角，相關人員可以確定投資優先順序、協調商業模式，並設計符合臨床需求和監管複雜性的生產佈局。

捐贈者准入、監管體系、報銷模式和製造舉措的地區差異如何影響全球市場的策略重點

血漿分餾生態系的策略決策持續受到區域動態的影響，而區域動態又受到捐贈者基礎可用性、法律規範、報銷環境和醫療服務提供模式差異的影響。在美洲，成熟的採集網路和對免疫球蛋白和凝血因子的高臨床需求支撐著強大的國內生產能力，而監管預期和付款人動態強調以結果為導向的證據和具有成本效益的治療方案。這種結合既為差異化產品創造了機會，也為透過流程現代化最佳化成本結構帶來了壓力。

歐洲、中東和非洲擁有多元化的管理體制和醫療基礎設施，這些地區在努力實現全部區域協調的同時，也採取了各國各自獨特的採購慣例。該地區的一些市場優先考慮國家自給自足和強力的藥物安全檢測，鼓勵投資本地製造能力並加強品管。同時，在某些地區，需求受到專科治療可近性的差異以及不斷演變的、獎勵臨床價值的報銷模式的影響。

亞太地區正在快速發展，這得益於醫療保健可及性的擴大、臨床應用的提升以及國內生物製造投資的不斷成長。一些政府正在積極推動生物技術能力建設，並支持官民合作關係，以擴大血漿採集和分離基礎設施。總而言之，區域策略必須將全球最佳實踐與本地區獨特的監管、經濟和臨床現實相協調，以確保在不同醫療保健體系中實現可靠的可及性和永續的營運。

競爭格局分為垂直整合製造商、專業合約分餾商和推動差異化和供應可靠性的技術合作夥伴

血漿分餾領域的競爭格局以垂直整合的製造商、專業的合約分離商以及提供賦能平台的技術提供者為特徵。領先的公司透過投資專有處理技術、可擴展的血漿採集營運，以及涵蓋免疫球蛋白、凝血因子和利基血漿衍生蛋白的廣泛治療產品組合來實現差異化。策略差異化越來越依賴端到端能力，這些能力能夠連接供體網路、賦能處理和臨床支援服務，從而提高可靠性和患者療效。

契約製造和專業加工合作夥伴發揮著至關重要的作用，他們提供靈活的產能和技術專長，幫助創新企業和學名藥快速進入市場。這些合作夥伴正在擴展一次性加工、先進層析法和無菌填充能力，以適應複雜的生技藥品和多樣化的劑型。技術供應商和分析公司正在透過提供製程控制工具、病毒清除方法和驗證框架，幫助加快監管核准並縮短上市時間。

在這種競爭格局下，成功的公司會部署一種緊密結合的策略，將有針對性的研發、策略夥伴關係關係、卓越營運專案與能力投資結合。他們還會優先考慮透明的供應鏈實踐、風險共擔的商業協議以及以患者為中心的服務，以維持與醫療服務提供者和付款人的長期合作關係。總體而言，規模、專業知識和合作夥伴關係的相互作用決定了該行業的競爭格局。

高階主管領導階層的可行策略重點是供應彈性、流程現代化、以病人為中心的商業化以及夥伴關係主導的創新

產業領導者應採取多管齊下的行動，以增強供應彈性，加速流程現代化，並使商業模式與不斷發展的臨床交付模式保持一致。首先，投資本地製造能力和多元化的供應商關係，可以減少貿易中斷和關稅波動帶來的風險，同時提高對本地需求的應對力。其次，優先考慮製程改進，例如實施層析法、超過濾和自動化控制系統，可提高產量、減少差異性，並長期降低單位成本。這些技術投資應與支援可比較性、病毒安全性和加速批次放行的增強型分析平台結合。

第三，公司應調整其商業性模式，以支持機構採購商和以患者為中心的醫療模式，開發基於套件的服務，包括靈活的劑量、家庭管理支援和依從性計劃。第四，應修訂合約框架，納入自適應供應協議、風險分擔條款以及協調合作夥伴之間獎勵的協作庫存管理方法。第五，公司策略應整合永續性和捐贈者管理舉措，以保障長期血漿供應。

最後，鼓勵企業與學術中心、專科診所和技術提供者建立策略聯盟，以加速創新，檢驗新的治療適應症，並降低監管途徑的風險。透過結合營運韌性、技術升級和夥伴關係主導的商業化，領導者可以在保持競爭優勢的同時，保障患者獲得重要治療方法的管道。

我們透過結合初步訪談、設施評估、文獻綜述和情境分析的主要調查方法來檢驗營運和策略見解。

本執行摘要所依據的研究整合了原始研究和二手資料，旨在對血漿分餾領域進行嚴謹客觀的分析。原始研究包括與行業高管、技術負責人、採購專家和臨床相關人員進行結構化訪談，以獲得關於生產限制、監管預期和最終用戶需求的實用見解。此外，我們還進行了現場考察和技術評估，以檢驗製程能力並了解不同分離設施之間的操作差異。

二次研究包括同行評審文獻、監管指南文件、技術白皮書和公開的企業資料，以三角測量技術趨勢和政策變化。在適用的情況下，數據與多個獨立資訊來源進行了交叉檢驗，以減少偏差並增強結論的證據力。分析方法包括定性主題分析、比較技術評估和基於情境的風險評估，以突顯策略意義和營運效益。

在整個研究過程中，我們謹慎地確保假設的透明度，澄清我們數據的來源，並承認其局限性，特別是在新技術和政策變化造成持續不確定性的領域。調查方法經過量身定做，旨在為尋求使研發、製造和商業活動與不斷發展的臨床和監管現實保持一致的決策者提供可行的見解。

綜合策略重點在於技術採用、供應多樣化以及協調的商業性和營運回應，以確保未來的競爭力

總而言之，血漿分餾產業正處於一個策略曲折點，技術進步、監管明晰和臨床模式的不斷發展正在共同重塑產品的開發、生產和交付方式。層析法和膜分離技術的日益成熟，加上捐贈者篩檢和分析技術的改進，正在提高產品質量，並實現更有利於患者的給藥方法。同時，不斷變化的貿易政策和捐贈者供應的地區差異，正促使企業投資於多元化的供應鏈和區域製造能力，以保障醫療服務的連續性。

價值鏈各相關人員的首要任務是將這些趨勢轉化為一種協作策略，在產能擴張與流程現代化和證據產生之間取得平衡。卓越的營運、有針對性的夥伴關係以及適應性的商業模式對於管理成本動態和確保滿足臨床需求至關重要。採用一種整合技術、商業性和地理因素的整體方法，將使組織能夠抵禦短期波動，同時獲得長期臨床影響和永續成長。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 重組療法的擴展推動了傳統血漿分餾體積的變化
  • 血漿分餾常規流程可提高效率並降低生產成本。
  • 免疫球蛋白治療需求的不斷成長推動了全球血漿採集基礎設施的投資
  • 影響血漿分餾和最終產品跨境分銷的監管協調挑戰
  • 採用奈米過濾和病毒去活化技術增強血漿衍生產品的安全性
  • 生物製藥公司與契約製造之間的策略夥伴關係擴大了全球血漿分餾能力
  • 由於外科手術和嚴重監護的增加，新興市場將推動血漿衍生白蛋白的需求增加
  • 數位捐贈者招募平台對血漿供應穩定性和採集中心利用率的影響

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章血漿分餾市場（依產品類型）

  • 白蛋白
  • 凝血因子濃縮物
  • 免疫球蛋白
    • 靜脈注射免疫球蛋白
    • 皮下注射免疫球蛋白
  • 蛋白酶抑制劑

第9章血漿分餾市場（依分離方法）

  • 離心
  • 冷沉澱
  • 乙醇沉澱
  • 離子交換層析法
  • 超過濾

第 10 章血漿分餾市場（按應用）

  • 血液學
  • 神經病學
  • 腫瘤學
  • 風濕病學

第 11 章血漿分餾市場（按最終用戶）

  • 學術機構
  • 臨床研究實驗室
  • 醫院和診所

第12章血漿分餾市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章血漿分餾市場：依類別

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章血漿分餾市場（按國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • 3M Company
    • ADMA Biologics, Inc.
    • Bharat Serums and Vaccines Limited
    • Bio Products Laboratory Ltd.
    • Biotest AG by Grifols, SA
    • China Biologic Products, Inc.
    • CSL Limited
    • Emergent BioSolutions Inc.
    • GC Biopharma corp.
    • HEINKEL Process Technology GmbH
    • Hemarus Therapeutics Ltd
    • Intas Pharmaceuticals Ltd.
    • Kamada Ltd.
    • Kedrion SpA
    • LFB SA
    • Merck KGaA
    • Octapharma AG
    • PlasmaGen BioSciences Pvt. Ltd.
    • Prothya Biosolutions BV
    • Shanghai Raas Blood Products Co. Ltd.
    • SK Plasma Co.,Ltd.
    • STERIS plc
    • Takeda Pharmaceutical Company Ltd.
Product Code: MRR-4312A385A58A

The Plasma Fractionation Market is projected to grow by USD 78.28 billion at a CAGR of 9.90% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 36.77 billion
Estimated Year [2025] USD 40.22 billion
Forecast Year [2032] USD 78.28 billion
CAGR (%) 9.90%

The plasma fractionation sector sits at the intersection of advanced bioprocessing and high-stakes clinical demand, driving critical therapies for immune deficiencies, coagulation disorders, and other life-threatening conditions. Recent advances in separation technologies, analytical platforms, and regulatory harmonization have elevated the technical expectations for manufacturers and service providers alike. In parallel, patient-centric care models and growing emphasis on rare disease therapeutics have shifted commercial priorities from commoditized supply toward differentiated delivery formats, such as subcutaneous immunoglobulin therapies, and integrated patient support programs.

Given these dynamics, stakeholders must reconcile increasing clinical complexity with the operational realities of sourcing high-quality plasma, maintaining batch-to-batch consistency, and ensuring robust cold-chain logistics. Strategic actors are prioritizing investments in automation, single-use systems, and process analytical technologies to reduce variability and accelerate time-to-release. Moreover, collaboration across the value chain-from blood collection networks to contract fractionators-has emerged as a competitive necessity, fostering partnerships that blend capacity with specialized regulatory and technical expertise.

As the industry matures, the emphasis on reproducible quality and resilient supply chains is matched by a growing focus on cost-to-serve and patient access. Consequently, corporate strategies are increasingly multidimensional, integrating manufacturing excellence, specialized product portfolios, and targeted geographies to capture clinical value while preserving margin integrity.

How technological breakthroughs, regulatory convergence, and shifting therapy delivery models are reshaping fractionation operations and strategic priorities

The past several years have ushered in transformative shifts across the plasma fractionation landscape, driven by technological innovation, regulatory evolution, and changing therapeutic needs. Upstream, enhanced donor screening protocols and improvements in plasma collection infrastructure have improved the quality profile of raw inputs, while downstream, modern fractionation modalities such as ion-exchange chromatography and ultrafiltration have enabled higher purity and yield for key biologics. These process improvements have not only increased product consistency but also expanded the repertoire of treatable indications by enabling formulations with improved stability and administration profiles.

Concurrently, regulatory agencies have converged on clearer expectations for viral safety, process validation, and comparability studies, prompting firms to modernize validation strategies and invest in advanced analytics. This regulatory clarity has lowered technical barriers for novel entrants but simultaneously raised the bar for demonstrating robust manufacturing controls. In the commercial sphere, the rise of subcutaneous immunoglobulin administration and patient self-administration models has reshaped distribution and adherence considerations, motivating manufacturers to rethink packaging, dosing flexibility, and patient education programs.

Finally, competitive dynamics have been influenced by a wave of strategic partnerships, contract manufacturing expansions, and cross-border capacity investments that aim to mitigate regional imbalances in plasma supply. Taken together, these changes are accelerating a shift from legacy batch-centric operations to agile, quality-driven platforms that support differentiated therapies and more resilient supply frameworks.

Implications of the 2025 United States tariff measures on supply chain resilience, sourcing strategies, contractual frameworks, and regional manufacturing

The imposition of tariffs in the United States in 2025 introduced a material variable into the global plasma fractionation supply chain, influencing sourcing choices, commercial contracts, and cross-border manufacturing strategies. Tariff-related cost pressures prompted firms to reassess import-dependent production models and to accelerate localization efforts for critical raw materials, specialized reagents, and finished formulations. In response, companies pursued diversified supplier networks and relocating or expanding manufacturing and fill-finish capabilities closer to demand centers to mitigate exposure to trade friction and logistical delays.

In the immediate aftermath, contract manufacturers and service providers saw adjustments to long-standing agreements as clients sought contractual provisions that addressed tariff volatility and potential passthrough of additional costs. These contractual shifts emphasized flexibility, shorter lead times, and contingency planning, while procurement teams prioritized multi-sourcing and regional redundancies. For products with complex cold-chain requirements or just-in-time logistics, tariff pressures amplified concerns about lead-time variability and inventory obsolescence, reinforcing the case for stronger demand forecasting and buffer strategies.

Over time, these trade policy shifts catalyzed strategic reorientation rather than one-off cost adjustments. Companies that invested in regional capacity, transparent costing mechanisms, and resilient supplier relationships found themselves better positioned to sustain operations and protect patient access. In contrast, organizations that remained heavily reliant on single-country supply chains faced elevated operational risk and needed to accelerate mitigation measures to preserve continuity of supply.

Integrated segmentation-driven insights linking product differentiation, fractionation methodologies, clinical applications, and end-user demands to strategic imperatives

Segmentation analysis reveals differentiated dynamics across product types, fractionation methods, applications, and end users that collectively shape strategic focus areas for industry participants. Within product categories, albumin, coagulation factor concentrates, immunoglobulins, and protease inhibitors show distinct development pathways; immunoglobulins, in particular, are further divided into intravenous immunoglobulin and subcutaneous immunoglobulin, with delivery route innovations influencing formulation and patient support requirements. These product-specific nuances drive divergent R&D priorities, regulatory requirements, and commercialization approaches.

Regarding production techniques, variations across centrifugation, cryoprecipitation, ethanol precipitation, ion-exchange chromatography, and ultrafiltration translate into different capital intensity, regulatory scrutiny, and scale economics. Players leveraging chromatographic and membrane-based methodologies are emphasizing process intensification and analytical control, while operations dependent on precipitation-based approaches are exploring hybrid process architectures to enhance yield and safety. In clinical application areas such as hematology, neurology, oncology, and rheumatology, therapeutic value propositions and reimbursement dynamics vary markedly, informing go-to-market strategies and evidence-generation plans.

Finally, the end-user landscape-spanning academic institutions, clinical research laboratories, and hospitals and clinics-dictates service-level expectations, regulatory oversight, and procurement behavior. Academic and clinical research settings often require flexible small-batch production and extensive documentation for investigational use, whereas hospitals and clinics prioritize reliable supply, dosing convenience, and support services that enable adherence and safe administration. Synthesizing these segmentation lenses enables stakeholders to prioritize investments, tailor commercial models, and design manufacturing footprints aligned with clinical demand and regulatory complexity.

How regional variations in donor access, regulatory systems, reimbursement models, and manufacturing initiatives are shaping strategic priorities across global markets

Regional dynamics continue to influence strategic decisions across the plasma fractionation ecosystem, driven by differences in donor base availability, regulatory frameworks, reimbursement environments, and healthcare delivery models. In the Americas, established collection networks and high clinical demand for immunoglobulins and coagulation factors have supported substantial domestic capacity, while regulatory expectations and payer dynamics emphasize outcome-focused evidence and cost-effective therapy delivery. This combination creates both opportunities for differentiated products and pressure to optimize cost structures through process modernization.

Europe, Middle East & Africa present a diverse mix of regulatory regimes and healthcare infrastructures, where pan-regional harmonization efforts coexist with country-specific procurement practices. Several markets in this region prioritize national self-sufficiency and robust pharmacovigilance, prompting investments in local production capabilities and tighter quality controls. Meanwhile, demand in certain territories is shaped by differential access to specialty therapies and evolving reimbursement models that reward clinical value.

Asia-Pacific exhibits a rapidly evolving landscape driven by expanding healthcare access, growing clinical adoption, and increasing investments in domestic biomanufacturing. Governments in several countries are actively promoting biotechnology capacity-building and supporting public-private partnerships to expand plasma collection and fractionation infrastructure. Taken together, regional strategies must reconcile global best practices with localized regulatory, economic, and clinical realities to enable reliable access and sustainable operations across diverse healthcare systems.

Competitive landscape shaped by vertically integrated manufacturers, specialized contract fractionators, and enabling technology partners driving differentiation and supply reliability

Competitive dynamics in the plasma fractionation sector are characterized by a mix of vertically integrated manufacturers, specialized contract fractionators, and technology providers offering enabling platforms. Leading organizations differentiate through investments in proprietary processing technologies, scale-efficient plasma collection operations, and breadth of therapeutic portfolios that span immunoglobulins, coagulation factors, and niche plasma-derived proteins. Strategic differentiation increasingly relies on end-to-end capabilities that link donor networks, validated processing, and clinical support services to enhance reliability and patient outcomes.

Contract manufacturing and specialized processing partners play a pivotal role by offering flexible capacity and technical know-how that enable faster entry for innovators and generics alike. These partners are expanding capabilities in single-use processing, advanced chromatography, and aseptic fill-finish to accommodate complex biologics and variant administration formats. Technology suppliers and analytics firms contribute by supplying process control tools, viral clearance methodologies, and validation frameworks that accelerate regulatory approval and reduce time-to-market.

Across the competitive landscape, successful companies deploy cohesive strategies that combine capacity investments with targeted R&D, strategic partnerships, and operational excellence programs. They also prioritize transparent supply chain practices, risk-sharing commercial agreements, and patient-centric services to sustain long-term relationships with healthcare providers and payers. Overall, the interplay of scale, specialized technology, and collaborative partnerships defines the competitive contours of the industry.

Actionable strategic priorities for executives focused on supply resilience, process modernization, patient-centric commercialization, and partnership-driven innovation

Industry leaders should pursue multifaceted actions that strengthen supply resilience, accelerate process modernization, and align commercial models with evolving clinical delivery paradigms. First, investment in regional capacity and diversified supplier relationships will reduce exposure to trade disruptions and tariff volatility while improving responsiveness to local demand. Second, prioritizing process intensification-through adoption of chromatography, ultrafiltration, and automated control systems-will improve yield, reduce variability, and lower unit cost over time. These technical investments should be paired with enhanced analytical platforms to support comparability, viral safety, and batch-release acceleration.

Third, firms must adapt commercial approaches to support both institutional purchasers and patient-centric care models, developing suite-based offerings that include flexible dosing, home administration support, and adherence programs. Fourth, contractual frameworks should be revisited to include adaptive supply agreements, risk-sharing clauses, and collaborative inventory management practices that align incentives across partners. Fifth, corporate strategies should integrate sustainability and donor stewardship initiatives to protect long-term plasma access, including donor engagement programs and transparent ethical sourcing practices.

Finally, organizations are advised to cultivate strategic alliances with academic centers, specialty clinics, and technology providers to accelerate innovation, validate new therapeutic indications, and de-risk regulatory pathways. By combining operational resilience, technological upgrade, and partnership-driven commercialization, leaders can sustain competitive advantage while safeguarding patient access to critical therapies.

Robust multi-source research methodology combining primary interviews, site assessments, literature review, and scenario analysis to validate operational and strategic insights

The research underlying this executive summary integrates primary and secondary approaches designed to ensure rigorous, objective analysis of the plasma fractionation landscape. Primary research included structured interviews with industry executives, technical leads, procurement specialists, and clinical stakeholders to capture practical insights on manufacturing constraints, regulatory expectations, and end-user requirements. These interviews were complemented by site visit observations and technology assessments to validate process capabilities and to understand operational heterogeneity across fractionation facilities.

Secondary research encompassed a review of peer-reviewed literature, regulatory guidance documents, technology white papers, and publicly available corporate disclosures to triangulate technical trends and policy changes. Wherever applicable, data were cross-validated against multiple independent sources to reduce bias and to strengthen the evidentiary basis for conclusions. Analytical methods incorporated qualitative thematic analysis, comparative technology evaluation, and scenario-based risk assessment to surface strategic implications and operational levers.

Throughout the research process, care was taken to ensure transparency of assumptions, clarity on data provenance, and acknowledgment of limitations, particularly where emerging technologies or policy shifts created areas of ongoing uncertainty. The methodology was calibrated to support actionable insights for decision-makers seeking to align R&D, manufacturing, and commercial activities with evolving clinical and regulatory realities.

Synthesis of strategic implications emphasizing technology adoption, supply diversification, and coordinated commercial and operational responses to secure future competitiveness

In conclusion, the plasma fractionation industry is at a strategic inflection point where technological advances, regulatory clarity, and evolving clinical models are converging to reshape how products are developed, manufactured, and delivered. The maturation of chromatographic and membrane-based fractionation technologies, paired with improved donor screening and analytics, is elevating product quality and enabling more patient-friendly administration options. At the same time, trade policy shifts and regional disparities in donor availability are prompting firms to invest in diversified supply chains and regional manufacturing capabilities to protect continuity of care.

For stakeholders across the value chain, the priority is to translate these trends into coordinated strategies that balance capacity expansion with process modernization and evidence generation. Operational excellence, targeted partnerships, and adaptive commercial models will be essential to manage cost dynamics and to meet clinical demand reliably. By embracing a holistic approach that integrates technical, commercial, and regional considerations, organizations can navigate near-term disruptions while positioning themselves to capture long-term clinical impact and sustainable growth.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of recombinant therapies driving shifts in traditional plasma fractionation volumes
  • 5.2. Integration of continuous flow processing to improve efficiency and reduce production costs in plasma fractionation
  • 5.3. Rising demand for immunoglobulin therapies prompting increased investments in global plasma collection infrastructure
  • 5.4. Regulatory harmonization challenges affecting cross-border plasma fractionation and final product distribution
  • 5.5. Adoption of nanofiltration and viral inactivation technologies enhancing safety profiles of plasma-derived products
  • 5.6. Strategic partnerships between biopharma and contract manufacturers to expand plasma fractionation capacity worldwide
  • 5.7. Emerging markets driving growth in plasma-derived albumin demand amid increasing surgical and critical care procedures
  • 5.8. Impact of donor recruitment digital platforms on plasma supply stability and collection center utilization rates

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Plasma Fractionation Market, by Product Type

  • 8.1. Albumin
  • 8.2. Coagulation Factor Concentrates
  • 8.3. Immunoglobulins
    • 8.3.1. Intravenous Immunoglobulin
    • 8.3.2. Subcutaneous Immunoglobulin
  • 8.4. Protease Inhibitors

9. Plasma Fractionation Market, by Method of Fractionation

  • 9.1. Centrifugation
  • 9.2. Cryoprecipitation
  • 9.3. Ethanol Precipitation
  • 9.4. Ion-Exchange Chromatography
  • 9.5. Ultrafiltration

10. Plasma Fractionation Market, by Application

  • 10.1. Hematology
  • 10.2. Neurology
  • 10.3. Oncology
  • 10.4. Rheumatology

11. Plasma Fractionation Market, by End-User

  • 11.1. Academic Institutions
  • 11.2. Clinical Research Laboratories
  • 11.3. Hospitals & Clinics

12. Plasma Fractionation Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Plasma Fractionation Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Plasma Fractionation Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. 3M Company
    • 15.3.2. ADMA Biologics, Inc.
    • 15.3.3. Bharat Serums and Vaccines Limited
    • 15.3.4. Bio Products Laboratory Ltd.
    • 15.3.5. Biotest AG by Grifols, S.A.
    • 15.3.6. China Biologic Products, Inc.
    • 15.3.7. CSL Limited
    • 15.3.8. Emergent BioSolutions Inc.
    • 15.3.9. GC Biopharma corp.
    • 15.3.10. HEINKEL Process Technology GmbH
    • 15.3.11. Hemarus Therapeutics Ltd
    • 15.3.12. Intas Pharmaceuticals Ltd.
    • 15.3.13. Kamada Ltd.
    • 15.3.14. Kedrion S.p.A.
    • 15.3.15. LFB SA
    • 15.3.16. Merck KGaA
    • 15.3.17. Octapharma AG
    • 15.3.18. PlasmaGen BioSciences Pvt. Ltd.
    • 15.3.19. Prothya Biosolutions B.V.
    • 15.3.20. Shanghai Raas Blood Products Co. Ltd.
    • 15.3.21. SK Plasma Co.,Ltd.
    • 15.3.22. STERIS plc
    • 15.3.23. Takeda Pharmaceutical Company Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. PLASMA FRACTIONATION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. PLASMA FRACTIONATION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PLASMA FRACTIONATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PLASMA FRACTIONATION MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PLASMA FRACTIONATION MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ALBUMIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ALBUMIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ALBUMIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ALBUMIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ALBUMIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ALBUMIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CENTRIFUGATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CENTRIFUGATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CENTRIFUGATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CENTRIFUGATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CENTRIFUGATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CENTRIFUGATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CRYOPRECIPITATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CRYOPRECIPITATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CRYOPRECIPITATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CRYOPRECIPITATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CRYOPRECIPITATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CRYOPRECIPITATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ETHANOL PRECIPITATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ETHANOL PRECIPITATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ETHANOL PRECIPITATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ETHANOL PRECIPITATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ETHANOL PRECIPITATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ETHANOL PRECIPITATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ION-EXCHANGE CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ION-EXCHANGE CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ION-EXCHANGE CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ION-EXCHANGE CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ION-EXCHANGE CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ION-EXCHANGE CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ULTRAFILTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ULTRAFILTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ULTRAFILTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ULTRAFILTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ULTRAFILTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ULTRAFILTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HEMATOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY RHEUMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY RHEUMATOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY RHEUMATOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY RHEUMATOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY RHEUMATOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY RHEUMATOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CLINICAL RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CLINICAL RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CLINICAL RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CLINICAL RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 127. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 129. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 131. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 142. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 144. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 146. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 154. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 156. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 158. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 160. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 190. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 192. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 194. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 196. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 197. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 202. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 203. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 204. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 205. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 206. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 207. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 208. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 228. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 229. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 230. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 231. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 232. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 233. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 234. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 235. GCC PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GCC PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GCC PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. GCC PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. GCC PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 240. GCC PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 241. GCC PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 242. GCC PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 243. GCC PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 244. GCC PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 245. GCC PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 246. GCC PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 259. BRICS PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. BRICS PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. BRICS PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. BRICS PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. BRICS PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 264. BRICS PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 265. BRICS PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 266. BRICS PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 267. BRICS PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. BRICS PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. BRICS PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 270. BRICS PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 271. G7 PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. G7 PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. G7 PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. G7 PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. G7 PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 276. G7 PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 277. G7 PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 278. G7 PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 279. G7 PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 280. G7 PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 281. G7 PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 282. G7 PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 283. NATO PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. NATO PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. NATO PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. NATO PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. NATO PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 288. NATO PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 289. NATO PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 290. NATO PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 291. NATO PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 292. NATO PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 293. NATO PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 294. NATO PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 300. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 301. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 302. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 303. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 304. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 305. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 306. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 307. CANADA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. CANADA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. CANADA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 310. CANADA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 311. CANADA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 312. CANADA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 313. CANADA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 314. CANADA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 315. CANADA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 316. CANADA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 317. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 319. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 320. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 321. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 322. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 323. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 324. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 325. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 326. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 327. BRAZIL